BLCL

EBV-transformed B cell line, B-Lymphoblastoid Cell Line

Cell Type:
B cell
Tissue Origin:
blood
Species:
human
Research Area:
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
C Z-001 2e6 80% 80% Plasmid (general) 2 µg 100 µl I/II/2b
C X-005 2e6 77% 70% Plasmid (general) 2 µg 100 µl I/II/2b
C Y-001 2e6 67% 80% Plasmid (general) 2 µg 100 µl I/II/2b

Citations

Categories:
Transfection 
Authors:
Satish Kumar , Joanne E Curran , Erika C Espinosa , David C Glahn , John Blangero  
In:
J Bio Med Opt (2020) 7(1): 124 
Categories:
Transfection 
Authors:
Kreijtz J, de Mutsert G, van Baalen C, Fouchier R, Osterhaus A, Rimmelzwaan G 
In:
J Virol (2008) 82(11): 5161-6 
Categories:
Transfection 
Authors:
Berkhoff EG, Geelhoed-Mieras MM, Verschuren EJ, van Baalen CA, Gruters RA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF 
In:
Clin Exp Immunol (2007) 148(2): 296-306 
Categories:
Transfection 
Authors:
Wang W, Epler J, Salazar LG, Riddell SR 
In:
Cancer Res (2006) 66(13): 6826-33 
Categories:
Transfection 
Authors:
van Baalen CA, Kwa D, Verschuren EJ, Reedijk ML, Boon AC, de Mutsert G, Rimmelzwaan GF, Osterhaus AD and Gruters RA 
In:
J Infect Dis (2005) 192(7): 1183-1190